Eli Lilly and Co (HAM:LLY) Short-Term Debt: €3,460 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:LLY Eli Lilly and Co HAM:LLY
96 GF Score
Price €1,005.00
GF Value €1,225.33
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Eli Lilly and Co Short-Term Debt?

Eli Lilly and Co HAM:LLY -3.50% 96 Short-Term Debt is €3,460 Mil as of Mar. 2026. GuruFocus rates HAM:LLY with a GF Score™ of 96/100 and a GF Value™ of €1,225.33 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Eli Lilly and Co's Short-Term Debt for the quarter that ended in Mar. 2026 was €3,460 Mil.

Eli Lilly and Co's quarterly Short-Term Debt increased from Sep. 2025 (€1,391 Mil) to Dec. 2025 (€1,396 Mil) and increased from Dec. 2025 (€1,396 Mil) to Mar. 2026 (€3,460 Mil).

Eli Lilly and Co's annual Short-Term Debt declined from Dec. 2023 (€6,331 Mil) to Dec. 2024 (€4,887 Mil) and declined from Dec. 2024 (€4,887 Mil) to Dec. 2025 (€1,396 Mil).

Eli Lilly and Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Eli Lilly and Co Short-Term Debt Related Terms

Eli Lilly and Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Short-Term Debt Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,361.40 1,417.04 6,331.43 4,886.74 1,396.29

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,715.17 4,962.45 1,391.32 1,396.29 3,460.00
HAM:LLY
96GF Score
Eli Lilly and Co HAM:LLY
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of €3,460 Mil mean?
Eli Lilly and Co (HAM:LLY) has a Short-Term Debt of €3,460 Mil as of Mar. 2026.
Is Eli Lilly and Co's Short-Term Debt too high?
Eli Lilly and Co's current Short-Term Debt is €3,460 Mil. Overall, Eli Lilly and Co has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Short-Term Debt compare to JNJ and ABBV?
Eli Lilly and Co's Short-Term Debt of €3,460 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Eli Lilly and Co's current Short-Term Debt is €3,460 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (HAM:LLY) is currently considered Modestly Undervalued. The stock's GF Value™ is €1,225.33, compared to a current price of €1,005.00 — trading 18% below its estimated fair value. The current Short-Term Debt is €3,460 Mil. Eli Lilly and Co's overall GF Score™ is 96/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Eli Lilly and Co (HAM:LLY), the current Short-Term Debt is €3,460 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (HAM:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of €1,005.00 is trading 18% below its estimated GF Value™ of €1,225.33. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for HAM:LLY:

  • Short-Term Debt: €3,460 Mil
  • GF Value™: €1,225.33 vs. price of €1,005.00 (18% below fair value)
  • GF Score™: 96/100 with 4 warning signs

No single metric tells the full story. See the HAM:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
96GF Score

Get the complete analysis for HAM:LLY

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1,005.00
Price
€1,225.33
GF Value